#United States #San Diego #Robbins LLP #Charming Medical #MCTA

Robbins LLP Takes Action Against Charming Medical, Limited

In a recent announcement, Robbins LLP has informed shareholders about a class action lawsuit that targets Charming Medical, Limited (NASDAQ: MCTA). This legal action is on behalf of all investors who purchased securities of the company between October 10, 2025, and November 12, 2025. The lawsuit arises from allegations against Charming Medical for engaging in a fraudulent stock promotion scheme, raising serious concerns about the integrity of the stock's performance.

Charming Medical, primarily known for its innovative integration of Traditional Chinese Medicine with modern health technology, reportedly experienced a significant spike in its stock price during the specified period, climbing from an initial public offering price of $4.00 to an impressive $29.36 per share. Notably, this surge occurred without any substantial news or developments from the company justifying such an increase. This anomaly has prompted investigations and led to the conclusion that the stock's rise was artificially influenced by a series of deceptive practices.

According to the class action complaint, the allegations against the defendants are multifaceted:
1. Fraudulent Promotion: The lawsuit claims that Charming Medical was at the center of a fraudulent stock promotion scheme that utilized misinformation spread through social media channels. Impersonators masquerading as reputable financial professionals allegedly misled investors, creating a false narrative that fueled a buying frenzy in the stock market.
2. Share Dumping: The allegations further state that company insiders used offshore accounts to systematically sell shares during a misleading campaign that inflated the stock's price, thereby benefiting from unsuspecting retail investors.
3. Lack of Disclosure: Claims also allege that Charming's public communications failed to disclose crucial information regarding the fabricated rumors and manipulative trading activities that impacted the stock's valuation.

As the market responded to these many allegations, the U.S. Securities and Exchange Commission (SEC) took action, halting trading for Charming Medical's stock on November 12, 2025, when the fraudulent practices came to light. The suspension of trading remains in effect as the company has been unable to provide necessary information to regulators, leaving investors in a state of uncertainty regarding their holdings.

How Can Investors Respond?

Investors of Charming Medical, Limited who believe they may have been adversely affected by these actions are being urged to consider their legal options. If you purchased shares during the timeline mentioned above, you may be eligible to participate in the class action. Robbins LLP is also inviting potential lead plaintiffs—individuals who act as representatives for other shareholders in directing the litigation—to reach out for further instructions.

Importantly, an investor's participation is not a requirement for recovery; those who prefer to remain uninvolved in the litigation can still benefit if a favorable outcome is reached.

All legal representation is offered on a contingency fee basis, meaning that shareholders will not incur fees, providing an accessible pathway for investors to seek justice without financial burden.

About Robbins LLP

Robbins LLP has established itself as a prominent entity in shareholder rights litigation since its inception in 2002. The firm is dedicated to assisting shareholders in recovering monetary losses, enhancing corporate governance frameworks, and holding company executives liable for misconduct. With a robust track record, Robbins LLP strives to protect the interests of investors and promote accountability within corporate structures.

For shareholders keen on staying updated regarding the class action status—especially if the case progresses towards a settlement—or those wishing to stay alerted about corporate malfeasance, signing up for their Stock Watch service could be beneficial. By doing so, investors can remain informed and empowered in navigating their financial decisions in response to corporate actions.

Investors facing challenges with Charming Medical, Limited are encouraged to contact Robbins LLP for guidance and further action—a step towards regaining control in the wake of the allegations now cast upon the company.